AMGEN INC
Nasdaq: AMGN·Thousand Oaks, California·CIK 0000318154
- Price
- $462.32
- Base IV
- $300.31
Valuation snapshot
At $462.32, the price sits between our base case ($300.31) and bull case ($503.60).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $300.31
- 65% of the price · range $145.57–$503.60
- Price vs base case
- 54% above
- $462.32 against $300.31
- Base case · our researched forecast, 2026-11-05See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has fallen 3.4% since this valuation was struck on 2026-11-05, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $145.57 to bull $503.60. Values per share.
Price against each value
- Bear case
- $145.57
- Price 218% above
- No growth
- …
- —
- Base case
- $300.31
- Price 54% above
What does Amgen do?
Amgen develops and makes medicines that doctors use to treat patients with cancer, heart disease, severe asthma, osteoporosis, inflammatory conditions and rare diseases.
It brought in $38.9B of sales in the 12 months to Sep 2026.
Led by Robert A. Bradway, Chairman and Chief Executive Officer since 2012. Robert A. Bradway | Amgen
- Industry
- Healthcare
- Based in
- Thousand Oaks, California
- Trades on
- Nasdaq as AMGN
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 24¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 29¢ of every dollar.
- Making what it sells29¢
- Research and development20¢
- Sales, marketing and admin18¢
- Interest and other costs4¢
- Tax4¢
- Left as profit24¢
Who pays Amgen, and for what?
Amgen is a biotechnology company that discovers, develops, makes and sells medicines for serious illnesses such as heart disease, bone loss, cancer, asthma and rare diseases. Almost all of its money comes from selling these medicines, about three-quarters of it in the U.S. The rest comes from royalties and payments from partner companies.
In the U.S., Amgen sells almost entirely to drug wholesalers; three of them (McKesson, Cencora and Cardinal Health) made up 77% of its gross revenues in 2025. The cost of the medicines is ultimately paid by government programs such as Medicare, private insurers and patients.
Heart and bone medicines
Repatha lowers cholesterol to cut heart-attack risk. Prolia and EVENITY treat osteoporosis. XGEVA prevents bone problems in cancer patients.
Repatha 140 mg/mL prefilled autoinjectorImage: Amgen Inflammation medicines
Medicines for immune-system conditions: ENBREL and Otezla for arthritis and psoriasis, TEZSPIRE for severe asthma and nasal polyps, and UPLIZNA.
TEZSPIRE 210 mg/1.91 mL prefilled pen · October 2025Image: U.S. National Library of Medicine Rare disease medicines
Medicines for uncommon conditions, including TEPEZZA for thyroid eye disease and KRYSTEXXA for hard-to-treat gout. Amgen gained most of these when it bought Horizon in 2023.
Cancer medicines
Cancer treatments, including BLINCYTO for a type of leukemia, KYPROLIS for multiple myeloma and IMDELLTRA for small cell lung cancer.
Biosimilars
Lower-cost versions of other companies' biologic drugs after their patents expire, such as AMJEVITA, WEZLANA and PAVBLU.
Other revenues
5%Royalties and payments from partner companies, not from Amgen's own drug sales. Product sales were $35.1 billion of about $36.8 billion in total 2025 revenue, so other revenues were roughly 4-5%.
Where its work physically happens, beyond headquarters:
- Amgen Juncos — Juncos, United States. Amgen performs a substantial majority of its commercial manufacturing at this biologics facility, making it the company's most consequential production site and a major supply-continuity exposure.
- Amgen Dún Laoghaire — Dún Laoghaire, Ireland. Amgen's largest manufacturing facility outside the United States formulates, aseptically fills, lyophilizes and packages medicines exported to more than 50 countries.
- Amgen Rhode Island — West Greenwich, United States. This multi-product campus manufactures commercial and clinical bulk drug substance and includes one of the world's largest mammalian-protein manufacturing facilities.
- Amgen Ohio — New Albany, United States. The FDA-licensed assembly and packaging plant is undergoing a $900 million expansion that will take Amgen's total Central Ohio investment above $1.4 billion.
- Amgen North Carolina — Holly Springs, United States. The opened drug-substance facility and second plant under construction represent more than $1.5 billion of planned investment intended to expand flexible biologics capacity as regulatory approvals are obtained.
How is the business doing?
Sales grew from $23B in 2016 to $36.8B in 2025, about 5% a year.
Running the business leaves about 32¢ of each sales dollar as operating profit, down from 43¢ in 2016.
After paying for its upkeep and new investment, it had $9.6B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Amgen says it exists to create new medicines for serious diseases and get them to patients.
“discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases”
Who is responsible for the plan?
- Robert A. BradwayChairman and Chief Executive Officer
He leads Amgen as its chief executive officer. Amgen earns most of its revenue from sales of human therapeutics.
- Murdo GordonExecutive Vice President, Global Markets and Policy
He leads Amgen’s global commercial, medical, access and government affairs capabilities. Those functions support access to Amgen’s marketed medicines around the world.
- James E. BradnerExecutive Vice President, Research and Development, Artificial Intelligence and Data
He oversees research and development, artificial intelligence and data. Amgen’s research and development work supports new human therapeutics and additional uses for marketed products.
Roles checked November 6, 2026.
What management says it is working on now:
Growing newer medicines
Management highlights six key growth medicines, including Repatha, EVENITY, TEZSPIRE, UPLIZNA and IMDELLTRA. In the second quarter of 2026 they grew 26% from a year earlier and made up nearly 70% of product sales.
Amgen Q2 2026 earnings release (Form 8-K)MariTide weight-loss program
Amgen is running several late-stage studies of its experimental weight-loss drug MariTide. They cover obesity with and without diabetes, heart outcomes, heart failure and sleep apnea, and three more diabetes studies start in 2026.
Amgen Q2 2026 earnings release (Form 8-K)Widening Repatha's use
After a large study showed Repatha cut major heart events by 25% in higher-risk patients, the FDA broadened its approval. Amgen is presenting more results from that study to doctors.
Amgen 10-K for fiscal 2025, Item 1 BusinessAdvancing the wider pipeline
Amgen is moving other experimental medicines through testing, including dazodalibep for Sjögren's disease, xaluritamig for prostate cancer and new uses for TEZSPIRE and UPLIZNA. It stopped some projects, such as AMG 513.
Amgen Q2 2026 earnings release (Form 8-K)Investing while returning cash
For 2026, Amgen plans about $2.6 billion of spending on facilities and equipment and up to $3.0 billion of share buybacks. It also keeps paying a quarterly dividend.
Amgen Q2 2026 earnings release (Form 8-K)
- Total revenues, full year 2026
- $38.2 billion to $39.4 billion
- Amgen Q2 2026 earnings release (Form 8-K)
- Adjusted (non-GAAP) earnings per share, full year 2026
- $22.30 to $23.50
- Amgen Q2 2026 earnings release (Form 8-K)
- Reported (GAAP) earnings per share, full year 2026
- $15.80 to $17.08
- Amgen Q2 2026 earnings release (Form 8-K)
What's changing right now?
Growth is holding steady. In Q3 2026 it sold 8% more than a year earlier. The year before, quarters averaged 9%.
Its operating margin is wider than a year ago: 36¢ per sales dollar, against 26¢.
Since Sep 2026 the share price has risen 4%, from $444.12 to $462.32.
Recently
September 30, 2026
Quarterly GAAP Operating Margin changed to 35.8%
Amgen Form 10-Q Q3 2026 Operating ResultsSeptember 30, 2026
Quarterly Revenue YoY Growth changed to 8.5%
Amgen Q3 2026 Form 10-QAugust 4, 2026
Second-quarter capital expenditure changed to $513.0M
Amgen Q2 2026 results
Coming up
Pending, 2026
TAVNEOS FDA hearing outcome
Amgen asked for a hearing on June 1, 2026 to challenge the FDA staff request to withdraw TAVNEOS, and filed supporting materials on July 23, 2026. The result decides whether the drug stays on the U.S. market.
Amgen Q2 2026 earnings release (Form 8-K)Second half of 2026
Late-stage results for dazodalibep and TEZSPIRE
Amgen expects to finish two late-stage studies of dazodalibep for Sjögren's disease, plus a late-stage study of TEZSPIRE for eosinophilic esophagitis, an inflammation of the food pipe.
Amgen Q2 2026 earnings release (Form 8-K)No earlier than late 2026 or early 2027
Tax Court decision
A U.S. Tax Court ruling on the IRS claims for 2010-2015 could change how much tax Amgen owes for those years.
Amgen 10-Q for the quarter ended June 30, 20262027
Medicare price for Otezla takes effect
A lower, government-set Medicare price for Otezla begins in 2027. In the second quarter of 2026, Otezla sales were already down 21% from a year earlier.
Amgen 10-K for fiscal 2025, Item 1A Risk Factors
Our own estimate moved too: the base case went from $258.02 to $300.31 a share between our last two valuations. The biggest reason: Quarterly GAAP Operating Margin moved from an unreported prior value to 35.8%, as reported in Amgen Form 10-Q Q3 2026 Operating Results.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Cheaper copies of older drugs
Patents on Prolia and XGEVA expired in 2025 and lower-priced copies have launched. In the second quarter of 2026, Prolia sales fell 32% and XGEVA sales fell 34%. Other drugs, including EVENITY, ENBREL, Otezla and Repatha, have patents expiring between 2026 and 2029.
From the company's own filingsWould hit how fast sales growAmgen 10-Q for the quarter ended June 30, 2026
U.S. government drug-price limits
Under the Inflation Reduction Act, Medicare has set much lower prices for ENBREL from 2026 and Otezla from 2027, and more drugs may follow. 'Most-favored-nation' pricing pressure adds to the uncertainty.
From the company's own filingsWould hit how much of each sale it keepsAmgen 10-K for fiscal 2025, Item 1A Risk Factors
Pressure from insurers and middlemen
A few large health plans and pharmacy benefit managers control about 89% of U.S. prescriptions, and three wholesalers handle most of Amgen's sales. That gives them strong leverage to push for lower prices and bigger discounts.
From the company's own filingsWould hit how much of each sale it keepsAmgen 10-K for fiscal 2025, Item 1A Risk Factors
Large tax dispute with the IRS
The IRS is seeking extra taxes for 2010-2015, a case now in Tax Court, and has proposed more for 2016-2018. Amgen is contesting both, but says the 2016-2018 adjustments could have a material effect on its finances if they stand.
From the company's own filingsWould hit the tax it paysAmgen 10-Q for the quarter ended June 30, 2026
Experimental drugs may fail
Amgen spent about $7.3 billion on research in 2025, but experimental drugs may never reach the market. Several programs, including MariTide for weight loss, face strong rivals.
From the company's own filingsWould hit how much it has to reinvestAmgen 10-K for fiscal 2025, Item 1A Risk Factors
Regulators can pull or pause products
FDA staff have asked Amgen to withdraw TAVNEOS from the U.S. market, and the FDA partly paused two studies of an under-the-skin form of BLINCYTO. Decisions like these can remove or delay sales.
From the company's own filingsWould hit how fast sales growAmgen Q2 2026 earnings release (Form 8-K)
Denosumab franchise accounted for over $6 billion in annual revenue, which will face pricing erosion as multiple biosimilar entrants launch.
From our researchWould hit how fast sales growAmgen Product Sales Tables in Form 10-K
Phase 3 MARITIME clinical program for MariTide across multiple cardiometabolic indications requires elevated annual R&D expenditure.
From our researchWould hit how much of each sale it keepsAmgen Pipeline Progress Report
Is it a good business?
From 2012 to 2025 it earned between 10% and 24% on the capital invested in it, a median of 13%. Its cost of capital in the latest valuation is 7.0%; returns were above it in every one of the 10 years.
From 2012 to 2025 it earned between 20% and 179% on its shareholders' equity, a median of 48%.
Over 10 years its operating margin ranged from 22¢ to 43¢ per sales dollar, a median of 31¢. Gross margin ran from 62¢ to 79¢.
Cost of capital 7.0%
The number of shares has held roughly steady over the past year.
It owes $40.8B more than it holds in cash, about 3.2 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $462.32. Our put its value between $145.57 and $503.60, with $300.31 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $145.57
This scenario assumes that upcoming generic competition for key mature medicines causes annual sales to briefly shrink and then stagnate below recent rates, while rising research costs reduce company profitability.
Base case, $300.31
This scenario assumes that sales of newer medicines for heart disease, bone health, and rare disorders offset generic patent losses to sustain moderate single-digit sales expansion while keeping company profits close to recent highs.
Bull case, $503.60
This scenario assumes that the company's experimental obesity therapy becomes a major commercial blockbuster and international sales surge, accelerating annual revenue gains well above recent trends and expanding business profitability.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 54%
For Amgen to be worth today's $462.32, sales would need to grow about 12.5% a year. We assume 4.1%. Over the last 5 years, sales grew 9.6% a year.
Or, if sales grow 4.1% as we assume, the price works with a profit margin of 48.0% (we assume 33.5%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 12.5% a year?
Try your own numbersWe're moderately sure of this range: it scores 62 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $300.31 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average4.1%
- Operating margin33.5%
- Long-term growth rate2.2%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$300.31 -35.0%


